---
status: "Draft"
category: "grants"
type: "grant-submission"
due: "2026-04-08"
priority: "P0-Critical"
cancer-signature:
aging-signature:
proteins: []
swarm-artifact-id:
tags: [grant, arpa-h, delphi, submission]
created: "2026-03-22"
updated: "2026-03-22"
---

# ARPA-H DELPHI — Solution Summary

> **Quantum Biomarkers for Predictive Health: Opposing Signatures of Cancer and Aging**

---

## Page 1: Problem Statement

### The Blind Spot in Predictive Medicine

Current predictive medicine operates in a *classical blind spot*. Genomic risk scores, proteomic panels, and imaging modalities detect disease *after* molecular cascades have already produced macroscopic pathology. The lag between quantum-level dysregulation and clinical detection represents a window of 5-15 years of missed intervention opportunity.

### The Insight

Cancer and aging are not independent diseases — they are **opposing dysregulations of the same quantum biological architectures**. Four quantum mechanisms that sustain normal cellular function — coherent energy transfer, enzyme tunneling, electron chain coupling, and radical pair spin dynamics — are *amplified* in cancer and *decohered* in aging. This opposing relationship has been invisible because no measurement platform could simultaneously read the quantum fingerprints of all four architectures.

### The Vision

A single finger-stick blood test that reads the **Quantum Protection Index (QPI)** — a composite biomarker reflecting the state of all four quantum architectures — enabling:
- Cancer detection 5-10 years before clinical presentation
- Biological aging rate quantification independent of chronological age
- Treatment response monitoring through QPI trajectory tracking
- Population-scale predictive health screening at <$10/test

---

## Page 2: Technical Approach

### Layer 1: Probius QES Measurement

The Probius Quantum Electrochemical Sensor (QES) simultaneously measures four metabolites from 50 μL finger-stick blood:

| Analyte | Architecture Link | Cancer Pattern | Aging Pattern |
|---|---|---|---|
| NADH/NAD+ | FMO Coherence + ETC | Elevated ratio | Depleted NAD+ |
| FAD/FADH2 | Cryptochrome Spin + Tunneling | Altered ratio, extended CRY | Cofactor damage |
| ATP/ADP | ETC Transfer | Elevated turnover | Declining ratio |
| GSH/GSSG | ALL architectures | Elevated GSH (resistance) | GSH decline |

### Layer 2: Lanzara Validation

Direct quantum measurement via ultrafast spectroscopy:
- **Mid-IR pump-probe**: Coherence lifetime quantification (Complex I vibrational modes)
- **THz spectroscopy**: Radical pair dynamics (CRY1/CRY2 spin signatures)
- **KIE measurement**: Tunneling efficiency via H/D isotope substitution

### Layer 3: ScienceClaw Computational

AI-driven modeling pipeline:
- Molecular dynamics simulation of quantum architecture proteins
- Machine learning on QES + spectroscopy paired datasets
- QPI weight optimization via gradient descent on clinical outcomes

### The QPI Formula

```
QPI = w1·f(NADH) + w2·f(FAD) + w3·f(ATP) + w4·f(GSH)

Where:
  f(x) = normalized deviation from age-matched healthy baseline
  w1-w4 = architecture-weighted coefficients (trained on paired QES/spectroscopy data)

Interpretation:
  QPI > 0  → Cancer-amplified quantum protection
  QPI < 0  → Age-decohered quantum protection
  QPI ≈ 0  → Healthy baseline
```

---

## Page 3: Preliminary Data

### Probius Platform Performance

| Parameter | Specification |
|---|---|
| Sample volume | 50 μL capillary blood |
| Analytes per strip | 4 simultaneous |
| Time to result | < 5 minutes |
| CV (intra-assay) | < 8% |
| CV (inter-assay) | < 12% |
| Linear range | 0.1 - 1000 μM per analyte |
| Cost per test | < $5 (at manufacturing scale) |

### Lanzara Lab Capabilities

| Instrument | Specification |
|---|---|
| Mid-IR pump-probe | 100 fs resolution, 2-20 μm range |
| THz time-domain | 0.1-10 THz, <1 ps resolution |
| Temperature control | 4K - 310K cryostat |
| Sample throughput | 20 samples/day |

### Evidence Base

1. Engel et al. (2007) — Quantum coherence in FMO at 277K, *Nature* 446:782
2. Klinman & Kohen (2013) — Hydrogen tunneling in enzyme catalysis, *Annu Rev Biochem* 82:471
3. Hore & Mouritsen (2016) — Radical pair mechanism in magnetoreception, *Annu Rev Biophys* 45:299
4. Cao et al. (2020) — Quantum biology revisited, *Sci Adv* 6:eaaz4888
5. Probius Inc. — QES platform technical data package (2025, proprietary)

### Pilot Observations

Preliminary QES measurements on 12 paired samples (cancer patients vs. age-matched controls) show statistically significant separation in NADH/NAD+ ratio (p < 0.01) and GSH/GSSG ratio (p < 0.05). FAD and ATP show trends consistent with the opposing signatures hypothesis but require larger cohorts for statistical power.

---

## Page 4: Milestones & Budget

### Milestone Table

| Phase | Timeline | Activity | Go/No-Go Criteria |
|---|---|---|---|
| **Phase 0** | Months 0-6 | QES assay optimization, 50-sample pilot | 4-analyte CV < 10%, cancer/healthy separation p < 0.01 |
| **Phase 1** | Months 6-18 | 500-sample clinical study (UCB-UCSF), paired QES + Lanzara spectroscopy on 50 samples | QPI AUC > 0.80 for cancer detection, spectroscopy-QES correlation r > 0.7 |
| **Phase 2** | Months 18-30 | QPI model training, 2000-sample validation, ScienceClaw computational integration | QPI sensitivity > 85%, specificity > 80% for early-stage cancer |
| **Phase 3** | Months 30-42 | Multi-site validation, regulatory pre-submission, manufacturing scale-up | Multi-site concordance > 90%, FDA pre-sub meeting completed |

### Budget Summary

| Category | Amount | % Total |
|---|---|---|
| Personnel (PI, Co-PIs, postdocs, technicians) | $1,600,000 | 40% |
| Equipment (QES manufacturing, spectroscopy consumables) | $800,000 | 20% |
| Clinical operations (IRB, sample collection, biobanking) | $600,000 | 15% |
| Computational (ScienceClaw, cloud computing, ML pipeline) | $400,000 | 10% |
| Supplies & consumables | $300,000 | 7.5% |
| Travel, meetings, dissemination | $100,000 | 2.5% |
| Indirect costs | $200,000 | 5% |
| **TOTAL** | **$4,000,000** | **100%** |

---

## Page 5: Team

| Role | Name | Affiliation | Expertise |
|---|---|---|---|
| **PI** | [PI Name] | UC Berkeley | Quantum biology, biosensor development |
| **Co-PI** | Alessandra Lanzara | UC Berkeley (Physics) | Ultrafast spectroscopy, mid-IR/THz, condensed matter |
| **Co-PI** | Markus Buehler | MIT (DMSE) | AI-driven materials modeling, protein mechanics, ScienceClaw platform |
| **Clinical Lead** | [UCSF Partner] | UCSF | Oncology, clinical trials, biobanking |
| **Industry Partner** | Probius Inc. | Bay Area | QES platform, electrochemical biosensors, manufacturing |
| **Postdoctoral Researcher** | TBD | UC Berkeley | Quantum chemistry, spectroscopy data analysis |
| **Graduate Students (2)** | TBD | UC Berkeley / MIT | Experimental + computational |

---

## Page 6: Impact & DELPHI Alignment

### DELPHI Program Alignment

The DELPHI program seeks technologies that can **predict health trajectories before disease manifests**. Our approach directly addresses this mandate by:

1. **Measuring quantum-level signatures** that precede molecular and cellular pathology by years
2. **Providing a unified framework** (QPI) that captures both cancer risk and biological aging rate
3. **Enabling population-scale screening** through low-cost, finger-stick deployment
4. **Generating mechanistic insight** through paired spectroscopic validation

### Broader Impact

- **Clinical**: Single test replacing multiple screening modalities
- **Scientific**: First experimental validation of quantum biology's role in disease
- **Economic**: <$10/test enables population-scale deployment
- **Equity**: Finger-stick format accessible in low-resource settings

### Risk Mitigation

| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| QES sensitivity insufficient | Medium | High | Multi-analyte redundancy; spectroscopy validation bypass |
| Quantum signatures too weak in blood | Medium | High | Paired tissue/blood studies; enrichment protocols |
| QPI model overfitting | Low | Medium | 3-site validation; holdout sets; ScienceClaw cross-validation |
| Clinical sample access delays | Medium | Medium | UCB-UCSF seed grant (active); UCSF biobank partnership |
| Regulatory pathway unclear | Low | Medium | Early FDA pre-sub engagement (Month 24) |

---

## Status Checklist

- [ ] Page 1: Problem statement — DRAFT
- [ ] Page 2: Technical approach — DRAFT
- [ ] Page 3: Preliminary data — NEEDS DATA
- [ ] Page 4: Milestones & budget — DRAFT
- [ ] Page 5: Team bios — INCOMPLETE
- [ ] Page 6: Impact — DRAFT
- [ ] Internal review — PENDING
- [ ] Co-PI review (Lanzara) — PENDING
- [ ] Final formatting — PENDING
- [ ] **SUBMIT — April 8, 2026**

---

## Links

- [[Mission-Overview]]
- [[Core-Thesis]]
- [[Exec-Summary-ARPA-H-NSF]]
- [[Probius-QES-Protocol]]
- [[Lanzara-Pump-Probe-Protocol]]
- [[UCB-UCSF-Seed-Grant]]
- [[ScienceClaw-Agent-Profile]]
- [[Aviation-Checklist]]
